CPS vs OMER Comparison

Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.